期刊文献+

替考拉宁治疗血液系统疾病合并重度革兰阳性球菌感染的临床观察 被引量:8

Teicoplanin on Treatment of Severe G^+ Cocci Infection in Patients with Hematological Diseases:A Clinical Observation
原文传递
导出
摘要 目的观察替考拉宁治疗血液系统疾病合并重度感染的临床疗效和安全性。方法对52例重度感染患者经验性使用或者根据细菌学检查结果使用替考拉宁注射液,疗程为5~12 d,观察用药前后患者的体温、临床症状、体征、化验室检查、微生物学检查、不良反应等。结果52例患者中临床治愈38例,占73.1%,显效5例,总有效率为82.7%;培养出革兰阳性球菌50株,清除41株,细菌清除率82.0%;不良反应发生率低,未发现与替考拉宁用药有关的肝肾功能损害、白细胞及血小板下降。结论替考拉宁治疗血液系统疾病合并重度感染疗效确凿,安全性高,如临床高度怀疑革兰阳性球菌重度感染患者,可考虑经验性使用。 OBJECTIVE To explore the therapeutic effectiveness and safety of the teicoplanin on treatment of severe G+ cocci infection in patients with hematological diseases.METHODS Fifty-two patients hospitalized in our department with severe bacteria infection received teicoplanin by infusion for 5-12 d.The temperature,clinical features,laboratory findings,microbiologic examination,and side effects were observed before and after the treatment.RESULTS From 52 patients,38 were cured(73.1%),while 5 cases were markedly improved.The total clinical effectiveness was 82.7%.Fifty strains of Gram-positive cocci were isolated and 41 strains were eliminated.The total bacteriological eliminated rate was 82.7%.The incidence of side effect was low and no damage of liver and kidney functions was observed.No related decrease in white blood cells and platelets count was observed.CONCLUSIONS Teicoplanin is an effective and safe agent to treat severe infections in hematological diseases.In patients highly suspected with G+ cocci infection,teicoplanin may be a choice for empirical treatment.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2010年第8期1141-1143,共3页 Chinese Journal of Nosocomiology
关键词 替考拉宁 血液病 细菌感染 革兰阳性球菌 Teicoplanin Hematologic Diseases Bacterial infections Gram-positive cocci
  • 相关文献

参考文献6

二级参考文献32

共引文献99

同被引文献49

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部